An Enquiry Form can be submitted to confirm the availability of a specific study.

• Clinical studies where data labels and/or supporting documents are not in English.
• Clinical studies of rare diseases. This is because anonymisation of these data is more difficult to achieve. For these studies GSK will assess the feasibility of anonymisation as part of the review of enquiries.
• Clinical studies where there are substantial practical/technical constraints to providing anonymised data. Examples include where data are not available in electronic format or data are images (e.g., X-Ray/MRI scan) or genetic/genomic data.
• Prematurely terminated trials that have insufficient enrolment/ exposure to warrant analysis may not be listed.

• Publication of the results of the primary endpoints, key secondary endpoints, and safety data; and
• Study product approval in the indication studied (in both US and EU, unless submission is planned for only one of the two regions in which case following approval in either US or EU as applicable, or if submission is not planned for either region first approval in any territory); or asset terminated across all indications.

Research teams must be appropriately qualified and should include a biostatistician to perform analyses.

GSK will provide access to the relevant data subset within a secure data access system. Interim data from clinical trials will generally not be shared by default, although efforts will be made to share such data in long-term, event-driven trials (such as oncology).

Data will not be provided to requesters where there is a potential conflict of interest, data is to be used for a commercial purpose or there is an actual or potential competitive risk.

Researchers are required to sign a Data Sharing Agreement.

🗹 Raw dataset. This is the dataset collected for each patient in the clinical study. Patient images from studies are not shared.

🗹 Analysis-ready dataset. This is the dataset used for GSK’s analysis and will be provided for studies that were completed in or after 2007. 

🗹 Protocols with any amendments. This describes the objectives, design, methodology, statistical considerations, and organization of a clinical study. The protocol is part of the appendices of the clinical study report.  

🗹 Annotated case report form. This is a blank case report form with descriptions of the data collected and how they are described in the dataset.  

🗹 Reporting and analysis plan. This describes methods of analysis, procedures for data handling and data displays (figures and tables) GSK used for the study.  

🗹 Dataset specifications. This is the meta-data which describes the datasets e.g., variable labels, variable descriptions, code lists, formats.  

🗹 Clinical study report Synopsis. This is a summary of the results.
* The (Anonymized) Full CSR will be made available upon request.

• The scientific rationale and relevance of the proposed research to medical science or patient care.  
• The ability of the proposed research plan (design, methods and analysis) to meet the scientific objectives.  
• Whether the proposal has potential to produce information that will enable identification of individual research participants. 
• The publication plan for the research. 
• Any real or potential conflicts of interest that may impact the planning, conduct or interpretation of the research and proposals to manage these conflicts of interest. 
• The qualifications and experience of the research team to conduct the proposed research review.

Rule-based approach derived from the industry best practices from PhUSE, TransCelerate, and Regulatory Guidance from EMA and Health Canada. The overall aim is for a pragmatic balance, ensuring an acceptably low risk of patient re-identification whilst retaining data utility.

The basic datasets researchers will access may look different from those submitted to regulators or used in publication(s) due to de-identification. As such, in some cases, researchers may not be able to completely duplicate the results of analyses.